A picture (or 3) worth a thousand words
TP53-mut acute erythroid leukemia….. Sinister.. 💀
The genome looks like it was attacked by a child playing with one of those geometric rulers…
#hemepath #leusm

Honored to be co-senior author on this effort led by Dr Della Porta combining GenoMed and Moffitt database. Moffitt Cancer Center Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of AHSCT in Pts With MDS | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

SCIENCE MATTERS!! 🧬
Major win for the #MDSsm field and our patients 🙌🏼🥳 #IPSSM
A huge congratulations & 🙏🏻 to all of you.
A testament to the impact of powerful & well-designed prognostication schemes by brilliant scientists Elli Papaemmanuil, PhD Elsa Bernard et al, combined…

Fresh in the 📪 the fabulous scent of newly printed paper!! 👌🏼
Nice to see this review by Sangeetha Venugopal MD,MS on TP53 mut myeloid neoplasms out in print!
#hemepath #mdssm #leusm

Tabletop by ☀️ vs. tabletop by 🌙
#PathologyLife

Thank you USCAP esp. Andrea Lindhart and team for hosting our MDS MPN course (with Drs. Hasserjian, Pozdnyakova and Mason)

The course was a huge success (and will be online soon) thanks to our ever engaging attendees…

The stain is RGB trichrome …

nature.com/articles/s4159…
#hemepath #pathx

Follicular lymphoma with abundant extracellular eosinophilic material, mimicking amyloid deposition: An unsual variant to be aware of #hemepath #lymsm #pathtwitter #MedEd #SoMe

Check a similar but more prominent case by Sanam Loghavi, MD صنم لغوی 🔬🧬 Blood Journal➡️ ashpublications.org/blood/article/…

A beautiful day in the desert 🏜️ to learn some #hemepath USCAP interactive microscopy center
My session: myeloid lymphoid neoplasms w/ eosinophilia #thinkpink
Today’s inspiration: Dr. Maude Abbott.. read her story 👇🏼what a trailblazer!

And you thought #Coachella was the hottest event in #palmsprings
Let’s get this USCAP #hemepath #MDSsm #MPNsm party started 🔬🎉 I feel like a kid in a candy store!! 🤩

With Drs. Rob Hasserjian , Olga Pozdnyakova, and Emily Mason!!

tour de force … lots of cool data to dig into
#hemapath Cell
Congrats to the authors
sciencedirect.com/science/articl…

3D pseudotime

Previously, only 3 translocations were considered 'AML defining' including t(8;21), inv(16) & APL with t(15;17). I found this article
tinyurl.com/3by26xju by Sanam Loghavi, MD صنم لغوی 🔬🧬 very interesting since these were extended to all (except 2 subtypes)‼️
#hemepath
youtu.be/w02ln_iPeZw?si…

A sincere thank you to chadi nabhan MD, MBA, FACP and Blood Cancers Today for an incredibly productive and thoughtfully planned inaugural #HOPLive24 and for providing us with the unique opportunity to brainstorm about the most relevant clinical questions across heme malignancies with the leading…

The most common topic at #HOPlive24 - MRD negativity matters, a lot!
#mmsm Sanam Loghavi, MD صنم لغوی 🔬🧬

Stellar panel to finish the first annual #HemOnc Pulse #HOPLive24 meeting with Naveen Pemmaraju, MD presenting on MPNs to be discussed by Ruben A. Mesa, MD Sanam Loghavi, MD صنم لغوی 🔬🧬 & Dr. Odenike.

Cannot be more pleased with all the discussions and debates.

Which #MDSsm patients are most likely to have UBA1 mutations associated with #VEXAS syndrome?

Our study now out in Blood Journal: Molecular and clinical presentation of UBA1-mutated MDS by Elli Papaemmanuil, PhD, Elsa Bernard, Maria Creignou, David Beck, MDS IWG-PM & MDS Foundation

This study's findings have profound impact for MDS patients lacking clear diagnostic & risk biomarkers. We emphasize the importance of UBA1 screening at diagnosis & need for correlative studies to guide future diagnostic criteria.

After hearing David Beck's discovery of UBA1 mutations in VEXAS Maria Sirenko Elsa Bernard in collaboration Maria Creignou & David, set out to investigate the role of UBA1 mutations in MDS patients lacking clinically relevant mutations. Read more in Blood Journal this week👇